Anti-CCL2 (Carlumab)-SMCC-DM1
Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker SMCC (HY-42360) and the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-CCL2 (Carlumab)-SMCC-DM1 can be used in the research of cancer, especially prostate cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
CCR2 |
Chemical Information
-
SMILES
[Anti-CCL2 (Carlumab)-SMCC-DM1]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53(10):1020-7. [Content Brief]
[2]. Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018 May 1;28(8):1363-1370. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)